文献速递炎症性肠病

急性COVID-19后综合征以炎症性肠病患者肠道病毒抗原持续存在为特征

Postacute COVID-19 is Characterized by Gut Viral Antigen Persistence in Inflammatory Bowel Diseases.
PubMed 文献 · Gastroenterology · 2022-05-01

本研究对46例炎症性肠病患者在确诊COVID-19后219天(范围94-257天)进行内镜检查,发现32例患者肠道黏膜表达SARS-CoV-2 RNA,24例患者病毒核衣壳蛋白持续存在于肠上皮和CD8+ T细胞中。病毒抗原持续存在与急性COVID-19严重程度、免疫抑制治疗和肠道炎症无关,且无法从组织培养出病毒。大多数病毒抗原持续存在患者报告急性COVID-19后综合征,而无抗原持续存在患者未报告。

要点

  • 46例炎症性肠病患者在COVID-19后约7个月,32例肠道黏膜可检测到SARS-CoV-2 RNA。
  • 24例患者肠上皮和CD8+ T细胞中持续存在病毒核衣壳蛋白。
  • 病毒抗原持续存在与急性COVID-19严重程度、免疫抑制治疗和肠道炎症无关。

核心结论

  • 结果表明SARS-CoV-2抗原在感染组织中持续存在是急性COVID-19后综合征的基础。
  • 病毒抗原持续存在引发免疫扰动和急性COVID-19后综合征的概念需要在对照临床试验中验证。

研究设计与样本

  • 内镜研究,纳入46例炎症性肠病患者,在确诊COVID-19感染后219天(范围94-257天)进行内镜检查。

主要发现

  • 46例患者中32例肠道黏膜表达SARS-CoV-2 RNA,24例肠上皮和CD8+ T细胞中持续存在病毒核衣壳蛋白。
  • 粪便中检测不到SARS-CoV-2抗原,病毒抗原持续存在与急性COVID-19严重程度、免疫抑制治疗和肠道炎症无关。
  • 无法从病毒抗原持续存在患者的肠道组织培养出SARS-CoV-2。
  • 大多数病毒抗原持续存在患者报告急性COVID-19后综合征,而无病毒抗原持续存在患者未报告。

局限性

  • 病毒抗原持续存在引发免疫扰动和急性COVID-19后综合征的概念需要在对照临床试验中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The coronavirus disease 2019 (COVID-19) pandemic has affected populations, societies, and lives for more than 2 years. Long-term sequelae of COVID-19, collectively termed the postacute COVID-19 syndrome, are rapidly emerging across the globe. Here, we investigated whether severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigen persistence underlies the postacute COVID-19 syndrome. METHODS: We performed an endoscopy study with 46 patients with inflammatory bowel disease (IBD) 219 days (range, 94-257) after a confirmed COVID-19 infection. SARS-CoV-2 antigen persistence was assessed in the small and large intestine using quantitative polymerase chain reaction of 4 viral transcripts, immunofluorescence of viral nucleocapsid, and virus cultivation from biopsy tissue. Postacute COVID-19 was assessed using a standardized questionnaire, and a systemic SARS-CoV-2 immune response was evaluated using flow cytometry and enzyme-linked immunosorbent assay at endoscopy. IBD activity was evaluated using clinical, biochemical, and endoscopic means. RESULTS: We report expression of SARS-CoV-2 RNA in the gut mucosa ∼7 months after mild acute COVID-19 in 32 of 46 patients with IBD. Viral nucleocapsid protein persisted in 24 of 46 patients in gut epithelium and CD8+ T cells. Expression of SARS-CoV-2 antigens was not detectable in stool and viral antigen persistence was unrelated to severity of acute COVID-19, immunosuppressive therapy, and gut inflammation. We were unable to culture SARS-CoV-2 from gut tissue of patients with viral antigen persistence. Postacute sequelae of COVID-19 were reported from the majority of patients with viral antigen persistence, but not from patients without viral antigen persistence. CONCLUSION: Our results indicate that SARS-CoV-2 antigen persistence in infected tissues serves as a basis for postacute COVID-19. The concept that viral antigen persistence instigates immune perturbation and postacute COVID-19 requires validation in controlled clinical trials.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Zollner A, Koch R, Jukic A, et al. Postacute COVID-19 is Characterized by Gut Viral Antigen Persistence in Inflammatory Bowel Diseases. Gastroenterology. 2022. PMID: 35508284. doi:10.1053/j.gastro.2022.04.037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。